Research › Fact Sheets › MRNA

MODERNA, INC.

LISTEDNASDAQ

SYMBOLMRNA

SIC2836

STATE OF INC.DE

FISCAL YEAR ENDSDecember 31

CIK1682852

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	590	6.4
Stockholders' equity	8,650	93.6
Total capitalization	9,240	100.0

399,235,889 shares outstanding at 24 July 2026 (cover page of the 10-Q filed 31 July 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, noncurrent	590

CAPITAL STOCK 12/31/25

Common shares authorized	1,600,000,000
Common shares issued	394,000,000
Par or stated value per share ($)	0.0001
Preferred stock ($ millions)	0
Outstanding at 7/24/26	399,235,889

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	–	–
2024	–	–
2023	–	–
2022	–	–
2021	–	–

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware. Formerly known as Moderna Therapeutics, Inc. (to 24 August 2016).

BUSINESS: Classified by the SEC under Standard Industrial Classification 2836, Biological Products, (No Diagnostic Substances). Large accelerated filer. Principal executive office: 325 Binney Street, Cambridge, MA 02142. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	1,944	3,236	6,848
Cost of revenues	868	1,464	4,693
Research and development	3,132	4,543	4,845
Depreciation and amortization	211	185	617
Operating income	(3,074)	(3,945)	(4,239)
Income before income taxes	(2,768)	(3,607)	(3,942)
Income taxes	54	(46)	772
Net income	(2,822)	(3,561)	(4,714)
Earned per share, diluted ($)	(7.26)	(9.28)	(12.33)
Dividends per share ($)	–	–	–

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Cash and equivalents	2,595	1,927
Receivables, net	184	358
Inventories	153	117
Total current assets	6,544	8,099
Property, plant and equipment, net	2,134	2,196
Goodwill	52	52
Total assets	12,338	14,142
Total current liabilities	1,987	2,206
Long-term debt	590	0
Total liabilities	3,688	3,241
Stockholders' equity	8,650	10,901
Total liabilities and equity	12,338	14,142

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	1,944	(3,074)	(2,822)	-145.2	(7.26)	–	(1,873)	192	(2,065)	12,338	3,688	590	8,650	-32.6	0.07
12/31/24	3,236	(3,945)	(3,561)	-110.0	(9.28)	–	(3,004)	1,051	(4,055)	14,142	3,241	0	10,901	-32.7	0.00
12/31/23	6,848	(4,239)	(4,714)	-68.8	(12.33)	–	(3,118)	707	(3,825)	18,426	4,572	–	13,854	-34.0	–
12/31/22	19,263	9,420	8,362	43.4	20.12	–	4,981	400	4,581	25,858	6,735	–	19,123	43.7	–
12/31/21	18,471	13,296	12,202	66.1	28.29	–	13,620	284	13,336	24,669	10,524	–	14,145	86.3	–
12/31/20	803	(763)	(747)	-93.0	(1.96)	–	2,027	68	1,959	7,337	4,776	–	2,561	-29.2	–
12/31/19	60	(546)	(514)	-853.7	(1.55)	–	(459)	32	(491)	1,589	415	–	1,175	-43.7	–
12/31/18	135	(413)	(385)	-284.8	(4.95)	–	(331)	106	(437)	1,962	432	–	1,530	-25.1	–
12/31/17	206	(269)	(256)	-124.3	(4.18)	–	(331)	58	(390)	1,084	459	–	(551)	46.4	–
12/31/16	108	(224)	(216)	-199.5	(3.79)	–	67	33	34	–	–	–	(335)	64.6	–

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

Moderna, Inc.
CIK 1682852 · EIN 81-3467528

PRINCIPAL OFFICE:

325 Binney Street, Cambridge, MA 02142
Tel.: 6177146500

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2836 · Biological Products, (No Diagnostic Substances)

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 20 February 2026

FORMER NAMES:

Moderna Therapeutics, Inc.

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

9/30/26	8-K	period 9/30/26
9/1/26	8-K	period 8/27/26
7/31/26	10-Q	period 6/30/26
7/31/26	8-K	period 7/31/26
7/8/26	8-K	period 7/6/26
5/11/26	8-K	period 5/6/26
5/1/26	10-Q	period 3/31/26
5/1/26	8-K	period 5/1/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/20/26) · 10-K FY2024 (filed 2/21/25) · 10-K FY2023 (filed 2/23/24) · 10-K FY2022 (filed 2/24/23) · 10-K FY2021 (filed 2/25/22) · 10-K FY2020 (filed 2/26/21) · 10-K FY2019 (filed 2/27/20) · 10-K FY2018 (filed 3/13/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.